Q4 2019 Alligator Bioscience AB Earnings Call Transcript
© -
Thank you. Welcome to this webcast on our year-end report 2019. I will start by giving an overview of significant events during the last quarter and on our pipeline strategy.
So slide 2. And as usual, the presentation includes some forward-looking statements.
Let's move to slide 3. This is a summary of the key events of the year. As of October 28, Alligator regained full rights to mitazalimab, previously ADC-1013. We have conducted a thorough technology transfer from Janssen and now have full control of the data, the IP, and the clinical material.
As intensive planning undergoing to bring mitazalimab or mita into the next stage of clinical development, clinical Phase 2. We have plans to submit CTA for Phase 2 combination trial during the autumn. Partner discussions are ongoing, both for the purpose of co-development and for potential out-licensing. That said, in order to build the value and not to lose speed and time, we will bring mita into Phase 2 with or without a partner.
I'd also like to give a brief
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |